Cypherpunk Technologies Inc., formerly Leap Therapeutics, reports developments tied to its transition from an oncology biotechnology company into an issuer with a digital asset treasury strategy focused on Zcash and its native coin, ZEC. The company changed its name in 2025, while continuing cancer research and development through a wholly owned subsidiary using the Leap Therapeutics name.
Recurring updates include ZEC treasury acquisitions, financing and capital-structure actions, board and leadership changes, quarterly financial results, and oncology program disclosures. The therapeutic pipeline referenced in company updates includes sirexatamab (DKN-01), a monoclonal antibody targeting DKK1, and FL-501, a monoclonal antibody targeting GDF-15.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.